[-] Show simple item record

dc.contributor.authorSando, Karen R.eng
dc.contributor.authorTaylor, Jameseng
dc.contributor.otherFamily Physicians Inquiries Networkeng
dc.date.issued2011eng
dc.description.abstractFor obese patients with type 2 diabetes (T2D) who do not tolerate other diabetes medications or for patients who need only a minimal reduction in glycosylated hemoglobin (A1c) to reach goal, bromocriptine may be a therapeutic agent to consider.eng
dc.identifier.urihttp://hdl.handle.net/10355/12126
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionPriority Updates to Research Literature (PURLs) (2011)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 60, no. 11 (November 2011): E1-E5.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subject.lcshNon-insulin-dependent diabeteseng
dc.subject.lcshDiabetes -- Treatmenteng
dc.subject.lcshBromocriptineeng
dc.subject.otherType 2 diabeteseng
dc.subject.otherObesityeng
dc.titleBromocriptine: Its place in type 2 diabetes Txeng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record